A share price of Intellia Therapeutics Inc [NTLA] is currently trading at $22.50, up 5.14%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The NTLA shares have gain 6.28% over the last week, with a monthly amount drifted -10.36%, and not seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Intellia Therapeutics Inc [NASDAQ: NTLA] stock has seen the most recent analyst activity on February 23, 2024, when Goldman downgraded its rating to a Neutral and also revised its price target to $32 from $136. On April 13, 2023, Canaccord Genuity initiated with a Buy rating and assigned a price target of $66 on the stock. Bernstein started tracking the stock assigning a Outperform rating and suggested a price target of $54 on March 21, 2023. BMO Capital Markets upgraded its rating to a Outperform and raised its price target to $57 on March 14, 2023. Cantor Fitzgerald started tracking with a Overweight rating for this stock on February 01, 2023, and assigned it a price target of $67. In a note dated January 24, 2023, Citigroup upgraded an Neutral rating on this stock and revised its target price from $48 to $39.
Intellia Therapeutics Inc experienced fluctuations in its stock price throughout the past year between $19.37 and $47.48. Currently, Wall Street analysts expect the stock to reach $131.76 within the next 12 months. Intellia Therapeutics Inc [NASDAQ: NTLA] shares were valued at $22.50 at the most recent close of the market. An investor can expect a potential return of 485.6% based on the average NTLA price forecast.
Analyzing the NTLA fundamentals
Trailing Twelve Months sales for Intellia Therapeutics Inc [NASDAQ:NTLA] were 36.27M which represents -114.12% decline. Gross Profit Margin for this corporation currently stands at 0.75% with Operating Profit Margin at -14.21%, Pretax Profit Margin comes in at -13.27%, and Net Profit Margin reading is -12.97%. To continue investigating profitability, this company’s Return on Assets is posted at -0.36, Equity is -0.43 and Total Capital is -0.43. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.11.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 21.35 points at the first support level, and at 20.21 for the second support level. However, for the 1st resistance point, the stock is sitting at 23.60, and for the 2nd resistance point, it is at 24.71.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Intellia Therapeutics Inc [NASDAQ:NTLA] is 8.67. Also, the Quick Ratio is 8.67, while the Cash Ratio stands at 1.97. Considering the valuation of this stock, the price to sales ratio is 59.83, the price to book ratio is 1.99.
Transactions by insiders
Recent insider trading involved BASTA JAMES, EVP, General Counsel, that happened on Mar 04 ’24 when 2297.0 shares were sold. EVP, Chief Technical Officer, Clark Eliana completed a deal on Mar 04 ’24 to sell 605.0 shares. Meanwhile, EVP, Chief Scientific Officer Sepp-Lorenzino Laura sold 2275.0 shares on Jan 08 ’24.
